Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
JAMA Network Open|December 1, 2020
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical TrialsJoshua E Reuss, Diana Stern, Jared C Foster, et al.Lung Cancer (Amsterdam, Netherlands)|August 13, 2023
High levels of expression of Trop-2 in thymic epithelial tumorsVincent Yeung, Jacob Zaemes, Justin Yeh, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2020
Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint InhibitorsOsama E Rahma, Joshua E Reuss, Anita Giobbie-Hurder, et al.Lung Cancer (Amsterdam, Netherlands)|February 9, 2025
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smokingJoshua E Reuss, Jacob Zaemes, Nishant Gandhi, et al.JTO Clinical and Research Reports|December 6, 2022
Remarkable Intracranial Response to Sotorasib in a Patient With KRAS G12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case ReportJustin Yeh, Jennifer A Marks, Ali H Alzeer, et al.Journal for Immunotherapy of Cancer|June 20, 2020
Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and managementJarushka Naidoo, Joshua E Reuss, Karthik Suresh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1Joshua E Reuss, Nofisat Ismaila, Amith Ahluwalia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2025
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1Joshua E Reuss, Sara Kuruvilla, Nofisat Ismaila, et al.Immunotherapy|July 3, 2026
Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysisNicolas Peruzzo, Gabriel Lenz, Rafael Alvim Pereira, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2025
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3Dwight H Owen, Nofisat Ismaila, Amith Ahluwalia, et al.Pageof 6